# OnCo record lung-squamous-cell-carcinoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/lung-squamous-cell-carcinoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "lung-squamous-cell-carcinoma" ;
  schema:name "Squamous cell carcinoma of the lung"@en ;
  schema:alternateName "Squamous-cell carcinoma of the lung"@en, "Lung squamous cell carcinoma"@en, "Squamous NSCLC"@en, "Squamous"@en, "Squamous cell carcinoma (~25-30%)"@en, "Epidermoid carcinoma of the lung"@en, "Keratinising and non-keratinising squamous cell carcinoma of the lung"@en ;
  schema:description "Squamous cell carcinoma is the second most common type of lung cancer and the one most tightly linked to smoking; it starts in the flat cells lining the large central airways. Unlike adenocarcinoma it rarely carries a mutation a tablet can target, so treatment rests on chemotherapy with immunotherapy, and pemetrexed and bevacizumab are not used."@en ;
  schema:url <https://onco.cc/cancers/lung-squamous-cell-carcinoma/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Squamous-cell_carcinoma_of_the_lung> ;
  schema:citation <https://www.cancer.gov/types/lung/hp/non-small-cell-lung-treatment-pdq>, <https://www.cancerresearchuk.org/about-cancer/lung-cancer/stages-types/types>, <https://doi.org/10.1016/j.jtho.2021.11.003>, <https://doi.org/10.1038/nature11404>, <https://doi.org/10.1016/s1470-2045(15)00021-2> ;
  onco:tag "subtype-page", "wave4", "lung" ;
  onco:related <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/lung-adenocarcinoma/>, <https://onco.cc/cancers/basaloid-squamous-cell-carcinoma-lung/>, <https://onco.cc/cancers/lymphoepithelial-carcinoma-lung/>, <https://onco.cc/cancers/large-cell-lung-carcinoma/>, <https://onco.cc/cancers/pdl1-high-nsclc/>, <https://onco.cc/cancers/lung-adenosquamous-carcinoma/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/nab-paclitaxel/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/necitumumab/>, <https://onco.cc/drugs/nedaplatin/>, <https://onco.cc/drugs/afatinib/>, <https://onco.cc/drugs/docetaxel/>, <https://onco.cc/drugs/ramucirumab/>, <https://onco.cc/drugs/cemiplimab/> ;
  onco:trials <https://onco.cc/trials/keynote-407/>, <https://onco.cc/trials/lung-map/>, <https://onco.cc/trials/lung-map-s1400i/>, <https://onco.cc/trials/sqnsclc/>, <https://onco.cc/trials/empower-lung-1/> ;
  onco:standardOfCare <https://onco.cc/trials/keynote-407/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/nab-paclitaxel/>, <https://onco.cc/drugs/cemiplimab/>, <https://onco.cc/cancers/pdl1-high-nsclc/>, <https://onco.cc/drugs/docetaxel/>, <https://onco.cc/drugs/ramucirumab/>, <https://onco.cc/drugs/afatinib/>, <https://onco.cc/trials/lung-map/>, <https://onco.cc/trials/lung-map-s1400i/>, <https://onco.cc/cancers/resectable-nsclc/>, <https://onco.cc/cancers/stage-iii-unresectable-nsclc/> .